The study aimed to validate the Prostate Cancer Comorbidity Index (PCCI) score in predicting other-cause mortality and cancer outcomes for men undergoing radical prostatectomy.
Data was collected from 4,857 men treated at the VA between 2000 and 2018, assessing risks of mortality and cancer recurrence based on the PCCI score using various statistical methods.
Results showed a clear correlation between higher PCCI scores and increased risks of both other-cause mortality and worse cancer outcomes, establishing the PCCI as a reliable tool for clinical decision-making in this patient population.